These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 30293157)

  • 1. Etanercept-induced Crohn's disease in ankylosing spondylitis: a case report and review of the literature.
    Tolu S; Rezvani A; Hindioglu N; Calkin Korkmaz M
    Rheumatol Int; 2018 Nov; 38(11):2157-2162. PubMed ID: 30293157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
    Toussirot É; Houvenagel É; Goëb V; Fouache D; Martin A; Le Dantec P; Dernis E; Wendling D; Ansemant T; Berthelot JM; Bader-Meunier B; Kantelip B;
    Joint Bone Spine; 2012 Oct; 79(5):457-63. PubMed ID: 22088934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept).
    Yazisiz V; Avci AB; Erbasan F; Yildirim B; Terzioğlu E
    Colorectal Dis; 2008 Nov; 10(9):953-4. PubMed ID: 18294265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crohn's disease in patients treated with etanercept.
    Valdivielso Cortázar E; Diz-Lois Palomares MT; Alonso Aguirre P
    Rev Esp Enferm Dig; 2020 Jan; 112(1):80-81. PubMed ID: 31793319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do Anti-TNF Agents Increase the Risk of Inflammatory Bowel Disease Evolution in Patients with Ankylosing Spondylitis? Real Life Data.
    Üsküdar Cansu D; Üsküdar Teke H; Temel T; Ertürk A; Kahraman O; Korkmaz C
    J Natl Med Assoc; 2019 Jun; 111(3):262-269. PubMed ID: 30389147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
    Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
    Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action.
    Haraoui B; Krelenbaum M
    Semin Arthritis Rheum; 2009 Dec; 39(3):176-81. PubMed ID: 18706681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crohn's disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature.
    Wiegering V; Morbach H; Dick A; Girschick HJ
    Rheumatol Int; 2010 Apr; 30(6):801-4. PubMed ID: 19506877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample.
    Yeaw J; Watson C; Fox KM; Schabert VF; Goodman S; Gandra SR
    Adv Ther; 2014 Apr; 31(4):410-25. PubMed ID: 24604700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease.
    Korzenik J; Larsen MD; Nielsen J; Kjeldsen J; Nørgård BM
    Aliment Pharmacol Ther; 2019 Aug; 50(3):289-294. PubMed ID: 31267570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice.
    Arends S; van der Veer E; Kamps FB; Houtman PM; Bos R; Bootsma H; Brouwer E; Spoorenberg A
    Clin Exp Rheumatol; 2015; 33(2):174-80. PubMed ID: 25797228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different effects of anti-TNF-alpha biologic drugs on the small bowel macroscopic inflammation in patients with ankylosing spondylitis.
    Chitul A; Voiosu AM; Marinescu M; Caraiola S; Nicolau A; Badea GC; Pârvu MI; Ionescu RA; Mateescu BR; Voiosu MR; Băicuş CR; Rimbaş M
    Rom J Intern Med; 2017 Mar; 55(1):44-52. PubMed ID: 28103201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.
    Kakkassery V; Mergler S; Pleyer U
    Curr Eye Res; 2010 Aug; 35(8):751-6. PubMed ID: 20673052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.
    Song IH; Appel H; Haibel H; Loddenkemper C; Braun J; Sieper J; Rudwaleit M
    J Rheumatol; 2008 Mar; 35(3):532-6. PubMed ID: 18203308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
    Braun J; Baraliakos X; Listing J; Davis J; van der Heijde D; Haibel H; Rudwaleit M; Sieper J
    Arthritis Rheum; 2007 May; 57(4):639-47. PubMed ID: 17471540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three cases of anti-TNF induced myositis and literature review.
    Zengin O; Onder ME; Alkan S; Kimyon G; Hüseynova N; Demir ZH; Kısacık B; Onat AM
    Rev Bras Reumatol Engl Ed; 2017; 57(6):590-595. PubMed ID: 29173693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance of Low Disease Activity following Tumor Necrosis Factor Inhibitor Dose Tapering in Ankylosing Spondylitis.
    Steel L; Gaffney K
    J Rheumatol; 2017 Aug; 44(8):1292. PubMed ID: 28765347
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.